Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®).

Heath, Matthew D; Mohsen, Mona O; de Kam, Pieter-Jan; Carreno Velazquez, Thalia L; Hewings, Simon J; Kramer, Matthias F; Kündig, Thomas M; Bachmann, Martin F; Skinner, Murray A (2020). Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®). Frontiers in immunology, 11, p. 594911. Frontiers Research Foundation 10.3389/fimmu.2020.594911

[img]
Preview
Text
shaping_modern.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

The concept of adjuvants or adjuvant systems, used in vaccines, exploit evolutionary relationships associated with how the immune system may initially respond to a foreign antigen or pathogen, thus mimicking natural exposure. This is particularly relevant during the non-specific innate stage of the immune response; as such, the quality of this response may dictate specific adaptive responses and conferred memory/protection to that specific antigen or pathogen. Therefore, adjuvants may optimise this response in the most appropriate way for a specific disease. The most commonly used traditional adjuvants are aluminium salts; however, a biodegradable adjuvant, MCT®, was developed for application in the niche area of allergy immunotherapy (AIT), also in combination with a TLR-4 adjuvant-Monophosphoryl Lipid A (MPL®)-producing the first adjuvant system approach for AIT in the clinic. In the last decade, the use and effectiveness of MCT® across a variety of disease models in the preclinical setting highlight it as a promising platform for adjuvant systems, to help overcome the challenges of modern vaccines. A consequence of bringing together, for the first time, a unified view of MCT® mode-of-action from multiple experiments and adjuvant systems will help facilitate future rational design of vaccines while shaping their success.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Mohsen, Mona Omar Mahmoud and Bachmann, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1664-3224

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Lee-Anne Brand

Date Deposited:

04 Jan 2021 16:51

Last Modified:

12 Mar 2021 07:12

Publisher DOI:

10.3389/fimmu.2020.594911

PubMed ID:

33324411

Uncontrolled Keywords:

MicroCrystalline Tyrosine (MCT®) Monophosphoryl Lipid A (MPL®) adjuvants allergy disease immunization vaccines virus-like particles

BORIS DOI:

10.48350/150597

URI:

https://boris.unibe.ch/id/eprint/150597

Actions (login required)

Edit item Edit item
Provide Feedback